BioCentury
ARTICLE | Finance

Seeking domestic partners

How the syndicate behind TCR2’s $125M series B could aid development in China

March 21, 2018 11:26 PM UTC

The syndicate behind TCR2 Therapeutics Inc.’s $125 million series B round includes a bevy of Chinese investors who could provide access to development and manufacturing partners in China.

6 Dimensions Capital and Curative Ventures led the untranched round. China-focused investors Hillhouse Capital, Syno Capital, Haitong International Securities and Lucion Group joined, as did fellow new investors Redmile Group, ArrowMark Partners, MiraeAsset Financial Group, Sirona Capital, Alexandria Venture Investments and Leerink Partners affiliates and existing investors MPM Capital, F2 Ventures and Cathay Fortune Capital Investment...

BCIQ Company Profiles

TCR2 Therapeutics Inc.